{
    "nct_id": "NCT06374212",
    "official_title": "A Prospective Open-label Trial Examining the Efficacy and Safety of Anifrolumab for Hidradenitis Suppurativa (HS)",
    "inclusion_criteria": "* Must be at least 18 years of age and older.\n* Diagnosis or history of clinical features consistent with hidradenitis suppurativa for ≥6 months prior to baseline visit\n* Must have an inflammatory lesion count of ≥5 at the time of screening\n* Must be off oral and intravenous antibiotics or on a stable course of oral antibiotics for ≥28 days prior to the baseline visit. Allowable antibiotics during treatment course are topical clindamycin, topical chlorhexidine gluconate, oral doxycycline, oral minocycline, or oral clindamycin.\n* Must have hidradenitis suppurativa in at least two distinct body locations, i.e. left and right groin\n* Does not have a history of or current Tuberculosis (TB)\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have had surgical intervention beyond incision and drainage in the last 8 weeks or have open surgical wounds\n* Planning a major elective surgery during the time of the study.\n* Taking other immunomodulatory or biologic treatment for Hidradenitis Suppurativa\n* Previous treatment with anifrolumab for any reason.\n* Are pregnant, lactating, or intend to become pregnant or lactate for up to 16 weeks following the last dose of study drug upon signing the Informed Consent Form (ICF)\n* Severe herpes zoster infection\n* Known history of allergy or reaction to any component of the study drug\n* History of cancer (some cases of basal cell carcinoma and squamous cell carcinoma of the skin as well as cervical carcinoma in situ may be eligible).\n* Primary immunodeficiency, splenectomy, or any underlying condition that predisposes participants to infection, or a positive HIV test.\n* Active Hepatitis\n* Clinical Cytomegalovirus or Epstein-Barr infection that has not completely resolved within 12 weeks prior to signing the informed consent.\n* Opportunistic infection that required hospitalization or intravenous antimicrobial treatment within 3 years of baseline.\n* Clinically significant chronic infection (e.g., osteomyelitis, bronchiectasis) within 8 weeks prior to signing the informed consent.\n* Any history of severe COVID-19 infection (e.g. prolonged hospitalization [hospitalization for observational purposes is not exclusionary]) or any prior COVID-19 infection with documented long COVID-19 and/or clinically significant unresolved sequelae. Any mild/asymptomatic infections COVID-19 infection (lab confirmed or suspected based on clinical symptoms) within the last 6 weeks prior to first dosing.\n* Abnormal laboratory tests indicating severe anemia, severely impaired liver function or immunosuppression.\n* History of, or current diagnosis of, catastrophic anti-phospholipid syndrome within 1 year prior to signing the informed consent. (Other degrees of anti-phospholipid syndrome that is adequately controlled by anticoagulants or aspirin for at least 12 weeks may be eligible).\n* History of or evidence of suicidal ideation within the past 6 months or any suicidal behavior within the past 12 months or recurrent behavior in the participant's lifetime.\n\nOther protocol-specific inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}